T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (2054)	5/23/2003 1:58:17 PM
From: JMarcus	Read Replies (1) of 2243

<<The biotech market has lately been more receptive of such models [long time-line, but huge ultimate potential].>> It is very interesting to compare the 2-year charts for GERN and AVGN. finance.yahoo.com GERN, which is much more constricted cash-wise and which also has a long time-line, has recently gone from roughly cash value at $1.42 per share to a high of $7.40 on 4-2-03, and is now showing strength in prices above $5.00. The chart shows GERN diverging from AVGN recently, but it has done so on good news. Anticipation of Avigen's news is starting to get priced into the stock but the full bump won't hit until the press releases (resumption of Coagulin-B trial and IND for the PD vector) are issued. Then maybe it will close the gap with GERN. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next